EFeCT
Efficient Fe Control in Thalassemics
EFeCT aims to repurpose drugs for reducing iron overload in Thalassemia.
The Science
Through in vivo drug screens we have identified drugs that can modulate the iron regulatory hormone, hepcidin.
Objectives
Testing the efficacy of Proton Pump Inhibitor drugs in reducing iron overload in thalassemia patients
Methodology
We propose to test the efficacy of proton-pump inhibitor (PPI) drugs in reducing iron overload in Non Transfusion Dependent Thalassemia (NTDT) patients. Enrolled patients would be prescribed a daily dose of 20mg Omeprazole for 18 months.
Collaborating on this Endeavour
Who can
We invite clinicians and research institutions to participate in this endeavor to re-purpose drugs for reducing iron overload in Thalassemia.
How to
We invite potential collaborators interested in pursuing this clinical study.
For more details, please email at chetana@igib.in
Protocol Document
Memorandum of Understanding
Patient Information / Consent
The Science in Detail
Through in vivo drug screens we have identified drugs that can modulate the iron regulatory hormone, hepcidin.
Know the Investigator
Chetana Sachidanandan is interested in understanding the mechanisms that operate to develop and maintain a functional liver and in developing new therapeutic interventions to prevent or treat breakdown of these processes. Her lab primarily uses the vertebrate model zebrafish (Danio rerio) to model liver biology.
CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB)
CSIR-Institute of Genomics & Integrative Biology (IGIB) is a premier Institute of Council of Scientific and Industrial Research (CSIR), engaged in research of national importance in the areas of genomics, molecular medicine, bioinformatics, proteomics and environmental biotechnology.
